2ndVote Society Defended ETF EGIS 深 滬
已收盤 08-03 16:00:00 美东时间
36.817
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 36.817
- 總市值 2945.36万
- 52周最高 37.41
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 28.4137
- 委 比 0.00%
- 總股本 80.00万
- 歷史最高 37.41
- 量 比 0
- 振 幅 0.00%
- 歷史最低 24.044
- 每 手 1
- 風險率 0.22%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多原油市场暗流涌动！交易员疯狂对冲美国祭出“终极黑天鹅”可能性
在流动性告急的市场中，嗅觉敏锐的原油交易员们正在疯狂下注，不仅防范中东断供的风险，更未雨绸缪防范一个足以震惊全球的极端政策……
05-05 22:39
BRIEF-Metaoptics Filed Registration Statement On Form F-1 With U.S. SEC On 4 May
BRIEF-Metaoptics Filed Registration Statement On Form F-1 With U.S. SEC On 4 May May 5 (Reuters) - MetaOptics Ltd METO.SI : FILED REGISTRATION STATEMENT ON FORM F-1 WITH U.S. SEC ON 4 MAY STATEMENT RELATING TO PROPOSED OFFERING OF ADSS IN CONNECTION WITH PROPOSED NASDAQ DUAL LISTING Further company
05-05 09:21
TXNM Energy Q1 GAAP EPS falls
TXNM Energy Q1 GAAP EPS falls Overview US regulated utility's Q1 ongoing EPS rose yr/yr; GAAP EPS declined sharply Company updated 2026-2030 capital investment plan to $10.2 bln Lower GAAP earnings due to higher unrealized investment losses and costs related to pending acquisition Outlook TXNM Energ
05-01 18:49
BRIEF-L3harris Announces Confidential Submission Of Draft Registration Statement For Proposed Initial Public Offering Of Missile Solutions Business
BRIEF-L3harris Announces Confidential Submission Of Draft Registration Statement For Proposed Initial Public Offering Of Missile Solutions Business April 29 (Reuters) - L3harris Technologies Inc LHX.N : L3HARRIS ANNOUNCES CONFIDENTIAL SUBMISSION OF DRAFT REGISTRATION STATEMENT FOR PROPOSED INITIAL P
04-30 10:08
BRIEF-Maze Therapeutics Announces $150 Million Registered Offering
BRIEF-Maze Therapeutics Announces $150 Million Registered Offering April 22 (Reuters) - Maze Therapeutics Inc MAZE.O : MAZE THERAPEUTICS ANNOUNCES $150 MILLION REGISTERED OFFERING MAZE THERAPEUTICS INC - PRICES 5,540,000 SHARES AT $23.50 PER SHARE Source text: ID:nGNX1XrGHs Further company coverage:
04-22 12:11
Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For Skin Cancer Treatment Ahead Of Event
Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today
04-13 19:14
Aegis Logistics launches ‘Saksham Niveshak’ drive to safeguard unclaimed investor dividends
Aegis Logistics Limited ( ($IN:AEGISLOG) ) has provided an announcement. Aegis ...
04-03 17:35
BRIEF-JD.Com Announces Proposed Offering Of CNY-Denominated Senior Notes
BRIEF-JD.Com Announces Proposed Offering Of CNY-Denominated Senior Notes March 31 (Reuters) - JD.Com Inc 9618.HK : JD.COM ANNOUNCES PROPOSED OFFERING OF CNY-DENOMINATED SENIOR NOTES TERMS OF NOTES TO BE DETERMINED AT TIME OF PRICING NET PROCEEDS TO BE USED FOR CORPORATE PURPOSES INCLUDING DEBT REPAY
03-31 09:28
BRIEF-Vor Bio Doses First Patient In Global Phase 3 Upstream Sjd Registrational Trial Of Telitacicept In Primary Sjögren’S Disease
BRIEF-Vor Bio Doses First Patient In Global Phase 3 Upstream Sjd Registrational Trial Of Telitacicept In Primary Sjögren’S Disease March 30 (Reuters) - Vor Biopharma Inc VOR.O : VOR BIO DOSES FIRST PATIENT IN GLOBAL PHASE 3 UPSTREAM SJD REGISTRATIONAL TRIAL OF TELITACICEPT IN PRIMARY SJÖGREN’S DISEA
03-30 21:47
Aegis Vopak Assigns Pipavav Ammonia Terminal Rights to Subsidiary ATPL
Aegis Vopak Terminals Limited ( ($IN:AEGISVOPAK) ) has issued an announcement. ...
03-27 02:15
